Skip to main content
Christopher Hoimes, DO, Oncology, Durham, NC

ChristopherJHoimesDO

Oncology Durham, NC

Genitourinary Oncology

Associate Professor of Medicine-Bladder/Renal and GU Oncology at Duke University

Dr. Hoimes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Hoimes' full profile

Already have an account?

  • Office

    20 Duke Medicine Cir
    Durham, NC 27710

Summary

  • Christopher Hoimes, is a genitourinary and Phase I oncologist on faculty at Duke University. He completed fellowships in hematology and medical oncology and genitourinary oncology at Yale University, and his residency in internal medicine at Penn State Hershey Medical Center. He has previously been on faculty at Penn State University, Yale, Case Western University.

Education & Training

  • Yale School of Medicine
    Yale School of MedicinePost-Doctoral Fellowship, 2008 - 2012
  • Yale-New Haven Hospital
    Yale-New Haven HospitalFellowship, Genitourinary Oncology, 2009 - 2010
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Penn State Milton S Hershey Medical Center
    Penn State Milton S Hershey Medical CenterChief Residency, Internal Medicine, 2005 - 2006
  • Penn State Milton S Hershey Medical Center
    Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 2002 - 2005
  • NYIT College Of Osteopathic Medicine
    NYIT College Of Osteopathic MedicineClass of 2001

Certifications & Licensure

  • OH State Medical License
    OH State License 2013 - 2026
  • NC State Medical License
    NC State License 2020 - 2025
  • CT State Medical License
    CT State License 2009 - 2013
  • PA State Medical License
    PA State License 2002 - 2012
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Books/Book Chapters

Lectures

  • EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer
    Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder CancerSeptember 28th, 2019

Professional Memberships